Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Shares Issued (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Shares Issued for 11 consecutive years, with $93.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued rose 2011.85% year-over-year to $93.2 million, compared with a TTM value of $95.4 million through Sep 2025, up 1665.91%, and an annual FY2024 reading of $6.9 million, up 1129.95% over the prior year.
  • Shares Issued was $93.2 million for Q3 2025 at CytomX Therapeutics, up from $177000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $107.7 million in Q1 2021 and bottomed at -$105.9 million in Q3 2021.
  • Average Shares Issued over 5 years is $6.5 million, with a median of $384000.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 4893.6% in 2021, while the deepest fall reached 2758.14% in 2021.
  • Year by year, Shares Issued stood at $683000.0 in 2021, then fell by 5.12% to $648000.0 in 2022, then decreased by 13.43% to $561000.0 in 2023, then skyrocketed by 266.67% to $2.1 million in 2024, then soared by 4430.68% to $93.2 million in 2025.
  • Business Quant data shows Shares Issued for CTMX at $93.2 million in Q3 2025, $177000.0 in Q2 2025, and $2.1 million in Q4 2024.